AU14 5
Alternative Names: AU14-5; Oral CDK2 inhibitorLatest Information Update: 11 Aug 2021
At a glance
- Originator Aucentra Therapeutics
- Class Amines; Antineoplastics; Imidazoles; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 26 Jul 2021 AU14 5 is available for licensing as of 26 Jul 2021. https://www.aucentra.com/partners-investors/
- 26 Apr 2021 Preclinical trials in Haematological malignancies in Australia (PO) before April 2021 (Aucentra pipeline, April 2021)
- 26 Apr 2021 Preclinical trials in Solid tumours in Australia (PO) before April 2021 (Aucentra Therapeutics pipeline, April 2021)